Bimekizumab is a humanised IgG1/Îș monoclonal antibody that selectively binds with high affinity to IL-17A, IL-17F and IL-17AF cytokines, blocking their interaction with the IL-17RA/IL-17RC receptor complex. Elevated concentrations of IL-17A and IL-17F have been implicated in the pathogenesis of several immune-mediated inflammatory diseases including plaque psoriasis.
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| BIMZELX Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Bimekizumab is an active ingredient of these brands:
United States (US)Australia (AU)Austria (AT)Canada (CA)Croatia (HR)Cyprus (CY)Estonia (EE)Finland (FI)France (FR)Ireland (IE)Israel (IL)Italy (IT)Japan (JP)Lithuania (LT)Poland (PL)Romania (RO)Spain (ES)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
